Compare GCBC & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCBC | XOMA |
|---|---|---|
| Founded | 1889 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.8M | 308.6M |
| IPO Year | 1998 | N/A |
| Metric | GCBC | XOMA |
|---|---|---|
| Price | $23.78 | $24.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $63.25 |
| AVG Volume (30 Days) | 11.7K | ★ 517.2K |
| Earning Date | 01-21-2026 | 03-16-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 39.39 | N/A |
| EPS | ★ 2.15 | 0.82 |
| Revenue | ★ $81,989,000.00 | $47,106,000.00 |
| Revenue This Year | N/A | $77.29 |
| Revenue Next Year | N/A | $29.30 |
| P/E Ratio | ★ $11.08 | $29.22 |
| Revenue Growth | 24.51 | ★ 118.02 |
| 52 Week Low | $20.00 | $18.35 |
| 52 Week High | $27.62 | $39.92 |
| Indicator | GCBC | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 39.03 |
| Support Level | $23.55 | $22.29 |
| Resistance Level | $24.42 | $27.87 |
| Average True Range (ATR) | 0.62 | 1.48 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 37.74 | 23.57 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.